Study S002373

GLP-1R Actions on Muscle and the Skeleton

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07154719
Acronym: GRAMS
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: RECRUITING
Enrollment: 50
Start: 2025-10-09
Primary completion: 2027-02-01
Lead sponsor: Pennington Biomedical Research Center
Conditions: Musculoskeletal Abnormalities; Obesity; Sarcopenic Obesity; Osteoporosis; Drug Effect
Interventions: DRUG:Tirzepatide; BEHAVIORAL:Lifestyle toolkit
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Changes in fat free mass (FFM) using DXA imaging. FFM equals all body composition that is not fat mass. This includes bone, skeletal muscle, organs, water and all connective tissues. The unit of measurement is in kilograms (kg) at baseline, 3 and 6 mo. [Baseline and time 3, and 6 months.]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0001315	Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps. Dubin RL, Diabetes, obesity & metabolism	2024	Narrative review	PMID 39344838 DOI	registry reference BACKGROUND:39344838
R0010987	Tirzepatide Once Weekly for the Treatment of Obesity. Jastreboff AM, The New England journal of medicine	2022	Randomized trial	PMID 35658024 DOI	registry reference BACKGROUND:35658024
R0023498	Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. Lundgren JR, The New England journal of medicine	2021	Randomized trial	PMID 33951361 DOI	registry reference BACKGROUND:33951361